Humana (HUM) FY2025 Earnings Quality Report

Grade: F — Three Failing Checks on Cash Conversion

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-19) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (2 critical audit matters: IBNR benefits payable valuation; Home Solutions goodwill and CON impairment)

One-line verdict: Humana's F grade comes from three failing checks — accounts receivable outpacing revenue for two consecutive years, a 68.9% collapse in operating cash flow, and goodwill-plus-intangibles equal to 61% of equity. The business fundamentals behind the failures are all visible in the 10-K: the benefit ratio jumped to 90.2% as medical costs rose faster than premiums, the company booked $449M of value creation charges, and it exited the Employer Group Commercial Medical Products business. Net income fell to $1.19B on $129.66B of revenue for a 0.9% margin. The M-Score could not be computed due to insufficient data in standardized formats. This is a managed-care profitability squeeze, not a manipulation concern.

Managed Care in the Medicare Advantage Era

From the 10-K: "Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for Medicare and Medicaid participants, families, individuals, military service personnel, and communities at large."

Humana operates through two reportable segments:

Insurance segment — per the 10-K: "Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits."

CenterWell segment — primary care, pharmacy solutions, and home health services, integrated as part of the company's value-based care strategy.

The revenue line keeps growing, but the profit engine is being squeezed. From the MD&A: "Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency."

Both ratios moved the wrong way in FY2025: benefit ratio up 40bps to 90.2%, operating cost ratio up 20bps to 12.0%. Those 60 basis points of combined deterioration on $129.66B of revenue is a ~$780M hit to operating profit — which matches the modest reported income growth.

From the MD&A income statement: "Total revenues 129,664 117,761 11,903 10.1 % Operating expenses: Benefits 110,812 100,664 10,148 10.1 % Operating costs 15,450 13,696 1,754 12.8 %"

Benefits expense grew 10.1% (matching revenue growth) but operating costs grew 12.8%, faster than revenue — absorbing the modest pricing gains.

Value Creation Initiatives and Impairment Charges

From the MD&A: "In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions. As a result of these initiatives, we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively, primarily within operating costs in the consolidated statements of income."

The 10-K breaks down the FY2025 $449M: "$329 million in severance and other employee related charges in connection with workforce optimization in 2025... as well as $40 million... in asset impairments in 2025... The remainder of the 2025 charges primarily relate to external consulting spend."

On top of this: "we recorded impairment charges of $253 million, $200 million and $91 million in 2025, 2024 and 2023, respectively. The impairment charges included impairment of indefinite-lived intangible assets for $128 million, $200 million and $55 million in 2025, 2024 and 2023, respectively, included within operating costs in our consolidated statements of income."

The cumulative drag from value creation charges plus impairments in FY2025 is approximately $700M pre-tax — a meaningful weight on an already-squeezed profit base.

The Employer Group Commercial Exit

From the MD&A: "During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings were materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans."

Cash Flow: The Sharp Decline

CFFO collapsed 69% from $2.97B in FY2024 to just $0.92B in FY2025 — triggering the A3 fail. Net income was flat at $1.19B, but cash conversion dropped from 2.46x to 0.78x in a single year. The decline reflects working capital headwinds: accounts receivable grew from $2.70B to $3.27B (+21%), partly because revenue growth outpaced premium collections and partly because of rising state Medicaid receivables.

The 18-Point Screening

Revenue Quality

A2 fail: Accounts receivable grew 20.8% in FY2025 vs revenue +10.1%, and in FY2024 AR grew 32.3% vs revenue +10.7%. Two consecutive years of AR outrunning revenue is a mechanical fail. For an insurer, a lot of the AR balance represents receivables from CMS (Medicare), state Medicaid agencies, and reinsurance — but even so the pace of growth exceeds what premium volume would explain.

A3 fail: Revenue grew 10.1% while CFFO dropped 68.9%. This is the single largest revenue-cash divergence in the screening set.

Expense Quality

HUM's income statement uses Benefits + Operating Costs rather than COGS + SG&A, so the gross margin and SG&A checks do not map cleanly onto yfinance's fields.

Cash Flow Quality

C1 watch: CFFO/NI of 0.78 is below the 1.0 threshold. In a stable year, Humana generates CFFO far above NI due to large actuarial reserves (IBNR in particular). The FY2025 ratio falling below 1 signals unusual working capital consumption.

C4 pass: Cash and short-term investments of $19.9B comfortably cover total debt of $12.4B. However, most of this cash is regulated subsidiary capital that supports insurance reserves — it is not freely available to meet parent-company obligations.

Balance Sheet

D1 fail: Goodwill of $9.69B plus intangibles of $1.13B = $10.82B, which equals 61% of the $17.66B equity base. The goodwill is concentrated in the CenterWell and Home Solutions businesses. PwC flagged the Home Solutions reporting unit goodwill as a critical audit matter: "the Company's goodwill balance was $9.7 billion as of December 31, 2025."

M&A Risk

Goodwill+intangibles declined 2% YoY, driven by the $128M indefinite-lived intangible impairment.

Beneish M-Score

Key Risks from Item 1A

1. Pricing and medical cost trend risk (the first-listed risk factor). From the 10-K: "If we do not design and price our products properly and competitively, if the premiums we charge are insufficient to cover the cost of health care services delivered to our members, if we are unable to implement clinical initiatives to provide a better health care experience for our members, lower costs and appropriately document the risk profile of our members, or if our estimates of benefits expense are inadequate, our profitability may be materially adversely affected." The 10-K continues: "Generally, premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums."

2. The long list of cost drivers outside Humana's control. The 10-K lists factors that can cause actual medical costs to exceed projections: "increased use of medical facilities and services, and the increased cost of such services; increased use or cost of prescription drugs, including specialty prescription drugs; the introduction of new or costly treatments, prescription drugs, or new technologies; our membership mix; variances in actual versus estimated levels of cost associated with new products, benefits or lines of business, product changes or benefit level changes; changes in the demographic characteristics of an account or market; changes or reductions of our utilization management functions such as preauthorization of services, concurrent review or requirements for physician referrals; changes in our purchase discounts or rebates received from manufacturers and wholesalers."

3. Competitive intensity and low entry barriers. From the 10-K: "We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do in some markets. In addition, other companies may enter our markets in the future, including emerging competitors in the Medicare or Medicaid programs or in the delivery of health care services. We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period."

4. IBNR benefits payable estimation — the first critical audit matter. From the PwC opinion: "the Company's incurred but not yet reported benefits payable (IBNR) was $6.6 billion as of December 31, 2025. Management develops its estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience." The $6.6B reserve is one of the largest estimates on Humana's balance sheet, and any change in assumption flows directly to net income.

5. Home Solutions goodwill impairment risk — the second critical audit matter. From the 10-K: "the Company's goodwill balance was $9.7 billion as of December 31, 2025" with PwC specifically calling out the Home Solutions reporting unit and Certificates of Need intangibles as CAMs.

Altman Z-Score and F-Score

Summary

Grade: F. Three failing checks (A2, A3, D1) reflect genuine operating stress.

Humana's F grade tracks real business deterioration documented throughout the 10-K. The benefit ratio expanded to 90.2%, operating cost ratio to 12.0%, and the combined 60bp squeeze consumed most of the 10.1% revenue growth. Value creation charges of $449M plus impairments of $253M reduced reported operating income. CFFO collapsed from $2.97B to $0.92B — a 69% decline — as working capital absorbed cash and receivables grew 21%.

Set against these pressures, the mitigating factors are modest but real: accruals ratio is a clean 0.5%, cash and short-term investments of $19.9B exceed total debt of $12.4B (though most is subsidiary-regulated), and the Employer Group Commercial exit removes a chronic loss-maker. The Home Solutions goodwill remains on watch per PwC's critical audit matter, and IBNR benefits payable of $6.6B is the single largest estimation risk on the balance sheet.

This is a managed-care profitability story. The F grade captures the cash-conversion deterioration and goodwill exposure, not any manipulation concern — though the absence of a computable M-Score means one of the key manipulation checks is missing from the evidence base.

**Disclaimer**: This report is based on Humana's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-19) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 2 critical audit matters)